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Abstract: Age-related macular degeneration (AMD) is the leading cause of irreversible 
blindness in developed countries. The role of complement in the development of AMD is 
now well-established. While some studies show evidence of complement dysregulation 
within the eye, others have demonstrated elevated systemic complement activation in 
association with AMD. It is unclear which one is the primary driver of disease. This has 
important implications for designing novel complement-based AMD therapies. We present 
a summary of the current literature and suggest that intraocular rather than systemic 
modulation of complement may prove more effective. 
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1. Introduction 
Age-related macular degeneration (AMD) is a common disease of the elderly and the leading cause 
of irreversible visual loss in the developed world [1]. Early AMD is characterised by the appearance of 
pigmentary changes and drusen in the retina. Loss of central vision occurs with disease progression 
either due to atrophy of the retinal pigment epithelial (RPE) cell layer and photoreceptors in geographic 
atrophy (GA), or haemorrhage or fluid exudation from choroidal neovascularisation (CNV) in 
neovascular (NV) AMD. GA is associated with gradual reduction in vision, whereas NV causes acute 
visual loss. While intravitreal injections of anti-vascular endothelial growth factor (VEGF) have 
revolutionised the treatment of NVAMD, an effective treatment for GA remains elusive [2]. 
The pathogenesis of AMD is complex and multifactorial. Age, environmental factors, genetic 
predisposition and oxidative stress are all thought to contribute [2]. An inflammatory model of AMD 
proposes that complement dysregulation can initiate and potentiate local inflammation at the retina in 
individuals with certain genetic and environmental risk factors [3]. Evidence for the role of 
complement, part of the innate immune system, in AMD began with the discovery that drusen contains 
various complement components and their regulators [4–8]. Such observations led to the concept that 
drusen, the clinical hallmark of early AMD, may act as foci of retinal inflammation. Following this in 
2005, landmark studies demonstrated an association between a polymorphism in the gene encoding 
complement factor H (CFH) and AMD development [9–12]. Several further risk variants in 
complement-related genes have since been discovered, including C2/CFB [13], C3 [14], possibly  
C7 [15], C9 [16], CFI [17] and SERPING [18], although some controversy exists over the significance 
of the latter [19]. The importance of these genes is supported by features exhibited by gene-specific 
knock-out mice. For example, CFH−/− mice show significantly reduced electroretinogram responses, 
increased subretinal fluorescent material, and disruption of RPE and photoreceptor cells, suggesting a 
protective role for CFH [20]. C3−/− [21] and C5−/− [22] mice display increased resistance to the 
development of laser-induced choroidal neovascularisation (CNV). In addition, a number of studies 
have demonstrated increased systemic complement activity in AMD patients compared with healthy 
controls [23–32].  
While altered complement deposition within the eye and increased systemic complement activation 
have both been demonstrated in AMD, it is unclear which one is the primary driver of disease. 
Clarifying this issue has important implications for designing novel complement-based therapies. This 
review provides an overview of the complement system, followed by a summary of the evidence for 
local and systemic dysregulation in AMD, and ends by comparing whether local intraocular or 
systemic complement activity is more important in AMD.  
2. The Complement System: An Overview 
The complement system encompasses a family of more than 30 circulating proteins and their 
regulators, playing a key role in host defence through pathogen recognition, opsonisation and lysis. It 
also performs important immunoregulatory functions, clearing immune complexes, inflammatory 
products and apoptotic cells, as well as bridging innate and adaptive immunity. Activation via the 
classical, lectin or alternative pathways triggers a sequential amplifying cascade of enzymatic reactions 
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(Figure 1). All three pathways converge with the production of a C3 convertase, which in turn 
produces a C5 convertase. This then activates the terminal pathway, culminating with formation of the 
membrane attack complex (MAC). The other effectors of the complement cascade are the 
anaphylatoxins, of which C5a is the most potent inflammatory mediator, and opsonins such as C3b.  
Figure 1. The complement cascade. Complement regulators are shown in grey boxes. 
Complement components and regulators which have known genetic associations with 
AMD are marked with an asterisk (*). Adapted from Khandhadia et al. 2012 [33].  
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The classical pathway is initiated upon binding of C1q to complement-fixing antibodies in immune 
complexes. Antibody-bound C1q is able to activate C1r and C1s. C2 and C4 are subsequently cleaved 
by activated C1s, producing C2a, C2b, C4a and C4b. The larger C4b and C2a fragments combine to 
form a C3 convertase (C4bC2a) which can cleave C3 into C3a and C3b. C3b binds to C3 convertase to 
form a C5 convertase (C4bC2aC3b) which cleaves C5 into C5a and C5b. C5b associates  
non-enzymatically with C6-C9, forming the MAC (C5b-C9). The MAC induces cell lysis by forming a 
pore-like structure in the phospholipid bilayer. 
Binding of mannan-binding lectin (MBL) to carbohydrate ligands on microbial cell surfaces 
activates the lectin pathway. MBL-associated serine proteases (MASP 1, MASP-2 and MASP-3) bind 
to these pattern-recognition molecules and the MBL-MASP-2 complex activates C4 and C2. C3 
convertase (C4bC2a) is formed and the complement cascade proceeds in the manner of the classical 
pathway thereafter.  
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In contrast to the classical and lectin pathways, the alternative pathway continuously self-activates 
at a low level via spontaneous hydrolysis of C3 into C3a and C3b. C3b binds to factor B (CFB), allowing 
factor D (CFD) to cleave CFB into Ba and Bb fragments. Bb remains attached to C3b to create C3bBb, 
the alternative pathway C3 convertase. This can cleave further C3 into C3a and C3b, forming the basis 
of an amplification loop. C3bBb binds to C3b to form C3bBb3b, the alternative pathway C5 
convertase. C3bBb3b converts C5 to C5a and C5b, leading to initiation of the terminal pathway. 
Numerous soluble and membrane-bound regulators are required to prevent uncontrolled complement 
activation. These act by degrading complement components and increasing convertase decay or by 
inhibiting MAC assembly. CFH is the most important fluid phase regulator and the main inhibitor of 
the alternative pathway. CFH catabolises C3b and accelerates C3 convertase decay. Complement 
factor I (CFI) degrades C3b and C4b, requiring cofactors such as CFH, membrane cofactor protein 
(MCP) or complement receptor 1. For further information on the complement system and its regulation, 
the reader is referred to the following reviews [34–36]. 
The complement system therefore exists in a delicate homeostatic balance between destroying 
pathogens and minimising damage to local tissues. Dysregulation is associated with a variety of 
diseases including SLE [37], atypical haemolytic uraemic syndrome [38], dense deposit disease [39], 
as well as AMD [33]. While increased complement activity may be beneficial for protection against 
infection in early life, chronic low-grade inflammation may prove detrimental in susceptible tissues 
with increasing age [40,41]. AMD studies have consistently implicated involvement of the alternative 
pathway in particular. As discussed above, the alternative pathway of complement activation is both 
spontaneously activating and self-perpetuating, providing a potential explanation for how complement 
could both initiate and amplify such inflammation. 
3. Intraocular Complement and AMD 
Intraocular complement production alters with age and in AMD. This may result in complement 
overactivity and contribute to retinal damage in AMD. The following section reviews the evidence for 
this process and the potential pathogenic mechanisms by which it may occur.  
3.1. Complement Production in the Ageing Retina 
While the majority of circulating complement is produced by the liver, a variety of tissues 
demonstrate extrahepatic complement synthesis [42]. The retina is one such example with production 
of some components approaching hepatic levels [9]. Anderson et al. showed using quantitative PCR 
that the human retina expresses a wide range of complement components and regulators, particularly 
those of the classical and alternative pathways. The choroid was the main source of complement 
proteins, whereas expression by the RPE and neural retina was mostly limited to a subset of alternative 
and terminal pathway regulators [3]. Resident microglia have also been recognised as a source of local 
complement. Luo et al. found that in vitro mouse retinal microglia constitutively produce complement, 
which is regulated by inflammatory cytokines interferon-gamma (IFNγ) and tumour necrosis  
factor-alpha (TNFα) [43]. 
Extrahepatic complement production may be necessary in tissues that are particularly vulnerable to 
infection or where delivery of circulating hepatic complement is limited [44]. The blood-retinal barrier 
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restricts access of plasma proteins to the eye and may explain the need for supplemental local 
production. Recent evidence also suggests a physiological role for complement in retinal function and 
neuronal survival [45]. Yu et al. showed that mice lacking receptors for C3a and C5a developed 
progressive early-onset retinal degeneration and were more susceptible to light-induced retinal 
dysfunction compared with wild type controls [46]. Hoh Kam et al. found more pronounced 
photoreceptor loss and Bruch’s membrane thickening in aged C3−/− mice compared with wild type 
controls, suggesting a protective role for C3 in the aged retina [47].  
Conversely it has been proposed that while local complement synthesis may be beneficial for early 
survival, it could theoretically increase susceptibility to damage from chronic low-grade overactivity in 
later years of life [3]. Indeed retinal production and deposition of complement appears to increase with 
advancing age. In studies of human donor eyes, immunohistochemistry showed that the majority of 
older subjects had MAC deposits in the RPE-choroid whereas this was rarely detectable in younger 
eyes [9,48]. Further evidence comes from studies on mice of differing ages. Mandal et al. showed 
greater expression of CFH in aged mice compared with younger mice [49]. Chen et al. also found that 
expression of C1q, C1r, C1s, C3 and CFB, as well as levels of C1q and C3 deposition in the 
RPE/choroid complex increased with age in mice [50]. A later study by the same authors suggested 
that increased complement activation might extend to the neuroretinal layer, as evidenced by increased 
deposition of the complement activation product C3d in the neuroretinas of older mice [51]. Similar 
results are reported by Faber et al., who in addition demonstrated higher expression of complement 
regulators CD59a and CFH in the neuroretinas of older mice [52]. More recently, intraretinal microglia 
extracted from older rats have been shown to express increased levels of C3 and CFB [53,54]. 
Expression of both complement components and their regulators therefore appear to increase with age. 
One possible explanation is that upregulation of complement regulators occurs in response to  
greater complement activity, the balance between these two processes determining susceptibility to 
complement-mediated retinal damage. 
3.2. Complement Production and Deposition in AMD 
Studies in mouse models suggest altered local complement production also occurs in AMD. Using 
reverse transcriptase PCR, upregulated retinal C1qβ [55] and C3 [56] expression has been shown in 
light-induced models of retinal degeneration. C3 expression was also upregulated in a laser-induced 
CNV model [57]. In addition, Bora et al. found upregulated local CFB expression in laser-induced 
CNV [22]. The same group also reported an initial decrease in CFH expression, which then increased 
again by day five post-laser [22,58]. CD59 followed a similar pattern, showing decreased expression 
following laser before increasing again by one week [59]. These findings collectively indicate a role 
for locally produced complement in retinal disease. The importance of retinal complement was perhaps 
most clearly demonstrated by Lyzogubov et al. Mice receiving subretinal injections of siRNA CFH 
showed a threefold reduction in retinal CFH production. Although hepatic levels of CFH and systemic 
alternative pathway activity remained unaltered, early onset and exacerbation of laser-induced CNV 
was observed in these mice compared with controls [58]. 
In human studies, immunohistochemical and proteomic studies have revealed differences in 
complement deposition comparing eyes from AMD patients with controls. Complement components 
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and regulators are a prominent component of drusen [4–8] and have also been found in surgically 
removed CNV [60–62]. Further to this, quantitative proteomics analysis of AMD cadaveric eyes has 
shown elevated levels of complement proteins in the macular Bruch’s membrane/choroidal complex 
compared with controls [63]. Another group found C3, CFB and CFD were elevated in the Bruch’s 
membrane/choroid interface at the macula in advanced AMD compared with early disease. Analysis of 
vitreous samples further revealed increased CFB activation in more advanced disease, which was 
attributed to a combination of CFH, C2, CFB and C3 genetic variants [64]. Homozygosity for the 
AMD-associated CFH Y402H polymorphism is also associated with increased MAC deposition at the 
RPE/choroid [65]. 
Other studies have found reduced levels of complement regulators in AMD donor eyes. Mullins et al. 
reported increased choroidal abundance of C1 inhibitor in AMD donor eyes compared with controls [66]. 
MCP is a membrane-bound complement regulator that has cofactor activity for CFI, acting at the 
convertase level of the complement cascade by inactivating C3b and C4b. Expression is normally on 
the basolateral surface of human RPE cells. Vogt et al. showed a reduction of MCP in early 
geographic atrophy, which was also associated with loss of polarity [67]. A more recent study 
additionally found reduced levels of CD59, a membrane-bound inhibitor of MAC formation, on RPE 
cells overlying drusen and geographic atrophy in AMD patients [68]. Interestingly CFH deposition in 
the retina is consistently greater in AMD compared to controls [9,69–71]. Perhaps this may reflect its 
importance in countering complement overactivation. Indeed, Hageman et al. showed that CFH  
co-localises with its ligand C3b/iC3b in drusen and co-distributes with MAC at the RPE/choroid [9]. 
3.3. Complement Activation and AMD: Pathogenic Mechanisms 
Intraocular complement activity therefore appears to increase with advancing age and in AMD. 
Elucidating the underlying reasons for this process is the subject of much current research. Some 
studies have examined how AMD-associated genetic variants, in particular the CFH Y402H variant, 
may alter complement function and therefore predispose to greater activity. Other investigations have 
revealed potential triggers for retinal complement activation including oxidative stress, pro-inflammatory 
agents produced in the retina and amyloid beta. These findings are discussed below. 
3.3.1. Functional Consequences of the CFH Y402H Genetic Variant 
The non-synonymous CFH Y402H polymorphism was the first complement-related genetic variant 
to be associated with AMD [9–12]. As a consequence, this has been the most extensively investigated 
variant in functional studies. However, it is not known whether the CFH Y402H variation has a direct 
influence on the pathogenesis of AMD, or whether it is a marker of an as yet unknown, perhaps more 
distal genetic defect.  
The CFH protein is a key plasma regulator of C3b, the central component in the alternative pathway 
of complement activation. It consists of 20 short complement regulatory (SCR) domains that represent 
binding sites for ligands including C3b, C-reactive protein (CRP) and heparin [72]. By recognising host 
tissues through interactions with surface polyanions it can deactivate deposited C3b [73]. SCRs 1–4 are 
involved in C3b binding, decay accelerating and CFI cofactor activity, hence regulating C3 convertase 
activity. SCRs 12–14 and 19–20 bind to the C3b proteolytic fragments C3c and C3d respectively [74]. 
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The risk CFH Y402H polymorphism leads to an amino acid change at position 402 of the  
CFH polypeptide, substituting tyrosine (Y402) for histidine (H402). Whereas other non-synonymous 
AMD-associated polymorphisms have been shown to directly affect alternative pathway  
activity [16,75–77], position 402 of the CFH protein lies within SCR7, which binds to streptococcal 
M6 protein, CRP and heparin [78]. CFH may therefore be especially important in protecting 
extracellular matrix structures like Bruch’s membrane, which do not express membrane-bound 
complement regulatory proteins. Clark et al. showed impaired binding of the AMD-associated  
H402 variant to glycosaminoglycans in Bruch’s membrane [79]. However, this was not replicated by 
Kelly et al. [80]. The H402 variant has also been found to bind less strongly to RPE cells by some 
studies [81,82], but again not by others [79,83].  
A more consistent finding is that the CFH H402 variant shows reduced affinity for CRP, an acute 
phase protein produced by the liver as part of the inflammatory response [81,83–88]. CRP associates 
with numerous ligands, allowing it to bind to the surface of damaged or apoptotic cells [89]. It can also 
bind CFH and may therefore recruit CFH to damaged cells [82]. Johnson et al. found homozygosity 
for CFH H402 to be associated with elevated levels of CRP in the RPE/choroid of human donor eyes, 
although not with local CFH protein levels. The authors concluded this could reflect reduced ability of 
the CFH H402 allotype to bind CRP at the retina [70]. This may result in less complement regulation 
and consequently greater local inflammation. Furthermore, CRP can interact with C1q to activate the 
classical complement pathway and may also therefore contribute to local inflammation [90]. Indeed 
higher levels of circulating CRP are associated with a greater risk of late-onset AMD development [91] 
and AMD progression [92]. In addition, elevated systemic CRP levels and homozygosity for CFH 
H402 synergistically increase the risk of late AMD and disease progression [93]. Bhutto et al. reported 
higher levels of CRP in eyes with early or NV AMD, as well as in non-atrophic areas of eyes with GA. 
In contrast to the findings from Johnson et al. [70], significantly lower levels of CFH were observed in 
these eyes, suggesting an inverse relationship between CFH and CRP levels in AMD [94]. 
Interestingly, both CRP and CFH levels were lower in atrophic areas of GA however [94], which the 
authors attributed to lower vascular supply at these regions [95].  
The CFH H402 protein variant also appears to be less protective against certain retinal mediators of 
oxidative stress. Weismann et al. investigated the interaction between CFH and malondialdehyde 
(MDA), a reactive decomposition product generated by lipid peroxidation of membrane phospholipids. 
CFH was shown to bind MDA and inactivate complement on MDA-bearing surfaces. However, this 
effect was diminished with the CFH H402 variant [69]. Oxidised phospholipids (oxPLs) represent 
another source of retinal oxidative stress. OxPLs are present in RPE cells and photoreceptors at the 
normal human macula and their levels have been shown to increase with age. Furthermore, eyes from 
AMD patients showed more intense immunoreactivity for oxPLs than age-matched control eyes [96]. 
Shaw et al. found that the protective CFH Y402 variant displayed greater binding to oxPLs and was 
more able to inhibit inflammatory effects on RPE cells and macrophages. By further showing that 
subretinal injections of oxPLs can induce CNV in mice, the authors concluded the CFH H402 variant 
may increase AMD-susceptibility through impaired ability to bind oxPLs [71]. 
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3.3.2. Potential Triggers for Complement Activation in AMD 
3.3.2.1. Oxidative Stress 
Oxidative stress is recognised as an important aetiological factor in AMD pathogenesis [2]. A 
number of studies suggest that oxidative stress may cause retinal damage through local dysregulation 
of complement. For example, IFNγ-induced synthesis of CFH by cultured RPE cells is reduced 
following treatment with hydrogen peroxide [97] and exposure to blue light [98]. Ebrahimi et al. 
reported decreased MCP and CD59, and increased CFB and C3b in RPE cells treated with oxidised 
low-density lipoproteins [68,99]. Thurman et al. showed that combined treatment of stable RPE cell 
monolayers with hydrogen peroxide and complement-sufficient serum disrupts barrier function, as 
well as reducing surface expression of membrane-bound complement regulatory proteins. Addition of 
either component alone had no effect [100]. Furthermore, sublytic MAC activation on oxidatively 
stressed RPE cells induced polarised secretion of VEGF [100], the amount of which was later found to 
correlate with the degree of induced barrier disruption [101]. Numerous studies on mouse models of 
laser-induced CNV have also shown that VEGF expression is dependent on complement activation, 
particularly via the alternative pathway [21,22,59,102–106]. These findings implicate complement 
activation as an important upstream mediator of VEGF secretion in NV AMD. 
Smoking is a well-known risk factor for AMD development and also associated with increased 
oxidative stress [2,107]. Wang et al. reported increased expression of C3a, C5, MAC and CFH in the 
RPE/choroid of mice with chronic cigarette exposure [108]. This was later to shown to be dependent 
on the alternative pathway of complement activation using a CFB−/− mouse model [109]. A recent 
study suggests smoking may activate complement via down-regulation of the antioxidant transcription 
factor Nrf2 [110]. Kunchithapautham et al. have additionally shown that mice exposed to cigarette 
smoke have increased retinal lipid deposition and that this is a complement-dependent process [111]. 
3.3.2.2. Pro-Inflammatory Agents Produced in the Retina 
Other groups have investigated the effects of pro-inflammatory agents that are generated at the 
retina. Zhou et al. found that photo-oxidised A2E, a bisretinoid lipofuscin pigment, can activate 
complement in human RPE cells in vitro [112] and that this is dependent on the alternative pathway of 
complement activation [113]. The authors further showed that pre-treatment of the RPE cells with 
vitamin E protected against photo-oxidation and complement activation [114]. Accumulation of  
photo-oxidised A2E in RPE cells has also been shown to decrease CFH expression [115]. Similarly, 
Ma et al. demonstrated that accumulation of intracellular A2E in cultured intraretinal microglia 
decreased CFH synthesis as well as increasing CFB production [116]. 
Chen et al. found that CFH synthesis by cultured RPE cells is also reduced by long-term treatment 
with oxidised photoreceptor outer segments [117]. More recently, Radu et al. showed that RPE cells 
with AMD-protective haplotypes, and not those with AMD-predisposing haplotypes, increased 
expression of CFH and other complement regulatory proteins when challenged with  
bisretinoid-containing Abca4−/− photoreceptor outer segments. This resulted in greater accumulation 
of C3/C3b and MAC on RPE cells [118].  
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Berchuck et al. showed that treating RPE cells with all-trans-retinal also results in decreased MCP 
and CD59 expression. Cell death was protected against by pre-treatment with the antioxidant 
resveratrol [119]. Hollyfield et al. immunised mice with carboxyethylpyrrole, an oxidation fragment of 
docosahexaenoic acid, which is an abundant fatty acid component of photoreceptor phospholipid 
membranes. These mice fixed C3 in Bruch’s membrane, accumulated sub-RPE drusen with age and 
developed GA-like lesions [120]. 
3.3.2.3. Amyloid Beta 
Amyloid beta (Abeta) is a major component of drusen and has been shown to co-localise with 
complement activation products within “amyloid vesicles” [121,122]. Wang et al. have found that 
Abeta binds CFI, inhibiting its ability to cleave and inactivate C3b [123]. The same group later showed 
that Abeta induced RPE cell production of monocyte chemoattractant protein-1, which can attract 
macrophages and microglia. It also increased TNFα and IL-1 beta production by macrophages and 
microglia, which up-regulated CFB production by RPE cells [124]. This is consistent with studies by 
Luo et al., who reported that expression of complement components by RPE and microglial cells is 
influenced by pro-inflammatory cytokines [43], and that activated macrophages can induce CFB and 
C3 expression by RPE cells [125]. Furthermore, CFH−/− mice injected intraperitoneally with anti-Abeta 
antibody showed reduced retinal deposition of Abeta and activated C3 in a dose-dependent manner [126]. 
4. Systemic Complement Activation and AMD 
Although the retina synthesises complement, the vast majority of circulating complement is 
produced by the liver. Complement deposited in the retina may therefore be of systemic origin. Several 
studies have investigated for an association between systemic complement dysregulation and AMD. 
The earliest was by Sivaprasad et al., who found significantly raised plasma levels of C3a-desArg, the 
inactive form of the pro-inflammatory C3a anaphylatoxin, in AMD subjects compared with controls [23]. 
A later study also showed elevated plasma C3a-desArg levels in subjects with NV AMD, but not in 
those with the non-NV form [31]. In a more comprehensive analysis Scholl et al. found levels of all 
complement activation products to be significantly raised in AMD subjects, especially the activation 
split products Ba and C3d, which indicate chronic activation [24]. Similar findings were reported by 
both Reynolds et al. [26] and in a larger study by Hecker et al. [25]. Reynolds et al. found a significant 
association between the highest quartiles of Bb and C5a plasma levels and advanced AMD [26]. 
Hecker et al. showed that a one standard deviation change in CFD, CFB, Ba and C3d plasma levels 
was associated with an almost fivefold increased risk of AMD [25]. More recently, analysis of 
haemolytic complement assays showed significantly increased systemic activity of the alternative 
pathway, but not of the classical or lectin pathways in association with AMD [28]. Ristau et al. 
conducted the largest study to date (n = 2655) finding a significantly raised plasma C3d/C3 ratio in 
AMD subjects, implying chronic complement activation [30]. 
While collectively these studies implicate elevated systemic complement activity in AMD, several 
discrepancies exist. For instance, significantly reduced plasma levels of CFD were associated with 
AMD in a study by Silva et al. [29], whereas Stanton et al. found significantly raised CFD levels in 
AMD subjects [27]. Raised plasma levels of MAC in AMD subjects were reported by Scholl et al. [24], 
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but not by Reynolds et al. [26] or Smailhodzic et al. [28]. Reynolds et al. suggested this may partly 
reflect the different proportions of AMD subtypes studied [26]. Indeed results from AMD subtype 
analyses, although inconsistent, suggest differential systemic complement activity. Scholl et al. 
showed significantly lower C3d levels in CNV subjects than in subjects with GA or early AMD [24]. 
In contrast to these findings Hecker et al. found a trend for greater increases in plasma levels of CFD, 
Ba and C3d in CNV subjects. A similar trend for greater increases in plasma CFD, CFB and Ba levels 
in GA subjects was observed, suggesting an association between AMD progression and systemic 
complement activation [25]. Reynolds et al. reported significantly higher plasma levels of Bb, C3a and 
C5a, and significantly lower plasma CFH levels in GA subjects specifically [26]. 
The effect of AMD-associated genetic variants on systemic complement activation is unclear. 
Hecker et al. found significantly raised plasma C3d levels in association with the single nucleotide 
polymorphism (SNP) rs2230199 in the C3 gene, and lower C3d levels in association with the minor 
allele for SNP rs800292 in CFH [25]. Consistent with this, Ristau et al. showed associations between 
the same SNPS in C3 and CFH with greater and lower C3d/C3 ratios respectively [30]. The risk 
genotype for SNP rs2230199 in C3 has also been found to be associated with higher plasma levels of 
C5a [26], although this was not replicated by Hecker et al. [25]. The protective CFB genotype for SNP 
rs4151667 has been associated with a significantly lower plasma CFB level [28] and C3d/C3 ratio [30]. 
In addition, Reynolds et al. showed an inverse relationship between plasma CFH levels and AMD risk 
for subjects with the non-protective CFB genotype for this SNP [26]. 
Apart from these examples however, reported associations between genetic variants and systemic 
complement activation have not been reproduced. For example while Smailhodzic et al. found an 
association between systemic complement activity and the CFH Y402H polymorphism [28], this was 
not reproduced by six other studies [23–26,29,30]. Indeed a stronger correlation between systemic 
complement and AMD has been identified at the protein level rather than with genetic variation [24]. 
This may indicate that analysing by individual SNPs is too simplistic an approach and does not 
account for interactions between multiple genetic variants. Heurich et al. showed that combining risk 
variants of AMD-associated complement protein allotypes resulted in sixfold greater haemolytic 
activity compared with protective variants in vitro [77]. Analysis of haplotypes at CFH and CFB-C2 
loci has also yielded further genetic associations with systemic complement activation, further 
suggesting that polymorphisms may have greater functional consequences in combination than 
individually [24,25,30].  
Alternatively, other factors may be more important in explaining systemic complement activation  
in AMD. Several groups found significantly increased systemic complement activation with  
advancing age [25,30,127], while others have shown gender-specific alterations in circulating 
complement levels [25,27,29]. High body mass index has been associated with increased complement 
activation [26,27], as well as a lower C3d/C3 ratio [30]. Ristau et al. also found a high C3d/C3 ratio 
was associated with smoking, whereas a low C3d/C3 ratio was associated with diabetes. Furthermore, 
the authors demonstrated in linear models that age, smoking status, gender, genetic polymorphisms 
and AMD status only explained <7% of the C3d/C3 ratio [30]. Gibson et al. similarly reported that 
only 8.8% of variation in plasma C1inh levels is attributable to age, gender, smoking, AMD status and 
SERPING1 genotype [32]. The major factors underlying systemic complement activation in AMD 
therefore appear to be largely unknown. 
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5. Systemic versus Local Manipulation of Complement 
Complement deposited in the retina could therefore be of either local or systemic origin, or both. 
The relative contribution from each source is yet to be determined. Insights into which is more 
important may, however, be indirectly inferred from studies of complement manipulation in AMD. 
Delivery of complement-modulating compounds via either systemic or local routes has shown 
promising results in laser-induced CNV mouse models. Agents inhibiting C3a [102], C5a [102],  
C6 [21,104], CFB [22] and MAC formation [128,129] have been reported to inhibit CNV 
development, as can administration of the complement regulatory molecules CD59 [59,103,130] and 
CFH [57,105,131]. 
In studies by Bora et al. [59] and Liu et al. [104], complement-modulating compounds were 
administered both systemically and locally, allowing some comparison of the two modes of delivery. 
Bora et al. found that recombinant soluble mouse CD59a-IgG2a (rsCD59a-Fc) fusion protein inhibits 
development of CNV when injected either via intravitreal (50 µg) or intraperitoneal (100 µg) routes  
24 hours before laser. The incidence of CNV in the group receiving intraperitoneal rsCD59a-Fc was 
13% compared with 94% for PBS-injected controls. For mice receiving intravitreal rsCD59a-Fc the 
incidence of CNV was reduced to 30% compared with 93% in PBS-injected controls [59]. In the study 
by Liu et al., mice either received eight daily intraperitoneal injections (50 µg) of anti-C6 antibody, 
with the last dose given immediately post-laser, or one subretinal dose (1.4 µg) immediately post-laser 
only. Compared with controls, CNV was inhibited by 77% and 73% at day three post-laser in mice 
receiving intraperitoneal and subretinal anti-C6 antibody injections respectively [104]. Although 
slightly greater inhibition of CNV development resulted from systemic rather than local administration 
in both studies, these differences were not reported as statistically significant. Furthermore, lower 
doses of these agents were required to achieve similar results when delivered locally. 
Clinical trials of potential complement-modulating therapies for AMD have mostly been 
disappointing [132]. However, results from a phase II clinical trial last year showed reduced GA 
progression in patients receiving intravitreal injections of lampalizumab, an anti-CFD monoclonal 
antibody [133]. Earlier this year Roche initiated two phase III clinical trials, Chroma [134] and  
Spectri [135], investigating GA treatment with lampalizumab. No results are available as these studies 
are still enrolling patients. In contrast systemic administration of an anti-C5 monoclonal antibody, 
eculizumab, had no effect on GA progression, despite almost complete inhibition of systemic C5 
activity. The authors suggested that systemic levels of eculizumab may not have been adequate to 
penetrate the RPE [136]. Consistent with this, the permeability of Bruch’s membrane to serum proteins 
has been shown to decrease with age [137] and a 50% decrease in choriocapillaris area has been 
observed underlying areas of GA [95]. It is conceivable that circulating complement-modulating 
therapies might reach retinal lesions more readily in NV AMD, where the blood-retinal barrier is 
breached. Indeed, Rohrer et al. demonstrated in a laser-induced mouse model that intravenously 
administered recombinant CFH (CR2-fH) reduced CNV size and localised to the RPE-choroid at sites 
of C3 deposition [57]. 
Eculizumab has also been investigated as a treatment for dense deposit disease (DDD) and C3 
glomerulonephritis (C3GN). Similar to AMD, these renal diseases are associated with systemic 
complement dysregulation and glomerular C3 deposition [39]. Furthermore, patients with dense 
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deposit disease often develop drusen [138,139]. Bomback et al. reported no change in drusen load or 
fundus autofluorescent pattern for two subjects with DDD/C3GN-related drusen, despite improvements 
in renal histology and laboratory parameters [140]. 
Another renal disease associated with complement-mediated glomerular damage is atypical haemolytic 
uraemic syndrome (aHUS). This too is associated with systemic complement activation and a number 
of genetic variants in complement-related genes, including CFH, C3, CFI, CFB and deletions in 
CFHR1-3 [141,142]. The kidney produces similar complement components to the RPE-choroid [3]. 
While kidney transplant alone is often unsuccessful in aHUS associated with a CFH gene mutation,  
co-transplanting a liver without a pathogenic CFH variant can achieve favourable long-term  
outcomes [143]. Furthermore, aHUS has been reported to develop in a patient receiving a donor liver 
carrying a pathogenic CFH genetic variant [144]. It appears therefore that circulating rather than 
locally produced CFH determines aHUS risk. This contrasts with observations from liver 
transplantation in AMD however. Khandhadia et al. showed that while circulating CFH protein allotype 
is completely determined by donor liver CFH genotype, AMD risk in liver transplant patients is 
associated with recipient rather than donor CFH genotype [145]. These findings suggest that unlike 
aHUS, locally produced CFH plays a greater role than circulating CFH in AMD pathogenesis. 
6. Conclusions 
In summary, the retina expresses its own set of complement proteins, which may render it more 
susceptible to complement-mediated damage. Indeed complement dysregulation and altered complement 
production seem to occur locally with advancing age and in AMD. A growing body of evidence 
indicates that intraocular complement plays a central role in AMD pathogenesis, interacting with other 
known risk factors such as oxidative stress and pro-angiogenic growth factors. Furthermore, an 
association between systemic complement activation and AMD has also been firmly established. 
Retinal deposition of circulating complement components or defective complement regulatory proteins 
may contribute to disease. 
Both locally and systemically produced complement could therefore play a role and compound one 
another in AMD. Determining the proportion of complement deposited in the retina that is locally or 
systemically produced might clarify which source is more important. This could potentially be directly 
investigated by analysing the relative proportions of complement protein allotypes in donor eyes from 
liver transplant patients with differing donor and recipient complement genotypes. Alternatively 
animal studies could determine whether tagged complement protein delivered systemically is deposited 
within the eye. Perhaps circulating complement may exert greater influence in NV AMD, where 
breakdown of the blood-retinal barrier affords greater access to the neuroretina. Despite these unanswered 
questions, current evidence from studies of local and systemic complement manipulation suggests 
intraocular delivery of novel complement-based therapies may prove more effective, particularly if the 
blood-retinal barriers are not compromised as is the case in early AMD and geographic atrophy. 
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